DelveInsight’s “Hyperphosphatemia Market Insights, Epidemiology, and Market Forecast-2032“  report delivers an in-depth understanding of the Hyperphosphatemia, historical and forecasted epidemiology as well as the Hyperphosphatemia market trends in the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

The Hyperphosphatemia market report provides current treatment practices, emerging drugs, Hyperphosphatemia market share of the individual therapies, and current and forecasted Hyperphosphatemia market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Hyperphosphatemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Hyperphosphatemia market.

Hyperphosphatemia Overview

Hyperphosphatemia is a condition characterized by an increase in serum phosphate level above 4.5 mg/100 mL. The condition usually occurs due to a decrement in renal function, commonly among chronic kidney disease (CKD) patients, in which phosphate levels shoot up abnormally high. Hyperphosphatemia does not usually have apparent symptoms. It is more likely that the symptoms of an underlying disease that can cause high phosphate levels, such as uncontrolled diabetes, are spotted first. More commonly, patients report uremic symptoms such as fatigue, shortness of breath, anorexia, nausea, vomiting, and sleep disturbances. If phosphate levels in the blood become too high, it may cause mineral and bone disorders and calcification. Also, hyperphosphatemia complexes serum calcium, decreasing the levels of ionized calcium and triggering PTH release, resulting in secondary hyperparathyroidism; this causes a high bone turnover state, releasing calcium from the bone to normalize the serum calcium level.

Hyperphosphatemia Epidemiology Insights

Rastogi et al. (2021) provided strategies to control hyperphosphatemia based on a systematic literature review of clinical trials and real-world observational data on phosphorus control in hemodialysis patients with CKD-mineral bone disorder (CKD-MBD). The study stated that although less than 5% of people with normal kidney function or those in CKD stages 1 and 2 exhibit hyperphosphatemia, the prevalence increases in CKD stage 3b and becomes incrementally higher in stages 4 (∼20%) and 5 (∼40%). By the time a patient receives dialysis, they are highly likely to be hyperphosphatemic. 

In 2021, in the United States, the prevalence of ESRD was approximately 803,000, and patients with ESRD on dialysis accounted for approximately 570,000 cases.

In the United States, the patients with Stage 3–5 CKD accounted for around 2,359,000 in 2021.

In the United States, in 2021, accounted for approximately 484,000 prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis. Among EU4 countries, Germany had the highest number of prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis, which was around 55,000 cases in 2021. Whereas, Spain accounted for the least number of prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis, which were around 23,000 cases in 2021.

Click here to learn more about the Hyperphosphatemia Market Landscape

The Report Covers the Hyperphosphatemia Epidemiology Segmented by:

Hyperphosphatemia is prevalent in cases 

Hyperphosphatemia prevelant cases 

Hyperphosphatemia stage-specific distribution

Hyperphosphatemia number of patients undergoing dialysis 

Hyperphosphatemia Market Outlook 

The Hyperphosphatemia market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Hyperphosphatemia market trends by analyzing the impact of current Hyperphosphatemia therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Hyperphosphatemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion, and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Hyperphosphatemia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Hyperphosphatemia market in 7MM is expected to witness a major change in the study period 2019-2032.

 Key Companies Working in the Hyperphosphatemia Market

Akebia Therapeutics

Vifor Fresenius Medical Care Renal Pharma

Astellas Pharma

Ardelyx

Shield Therapeutics

And many others 

Hyperphosphatemia Therapies Covered and Analyzed in the Report:

Ibsrela (tenapanor)

PT20

EOS789 

Fosrenol (Lanthanum Carbonate)

KHK7791

And many others 

Learn more about the Hyperphosphatemia Key Companies and Emerging Therapies in the Hyperphosphatemia  Market

Table of Contents 

Key Insights 

Hyperphosphatemia  Introduction 

Executive Summary of Hyperphosphatemia   

Disease Background and Overview

Epidemiology and patient population

Hyperphosphatemia  Emerging Therapies

Hyperphosphatemia  Market Outlook

Market Access and Reimbursement of Therapies

Market Drivers 

Market Barriers 

Appendix

Report Methodology

DelveInsight Capabilities

Disclaimer

Learn about the detailed offerings of the report @ Hyperphosphatemia Market Outlook 

Related Reports 

Hyperphosphatemia Epidemiology Forecast to 2032

DelveInsight’s “Hyperphosphatemia – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Hyperphosphatemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Trending Reports by DelveInsight

Adalimumab Biosimilar Market

Arbovirus Infection Market

Artificial Pancreas Device System Market

Dental Equipment Market

Gluten Sensitivity Market

Hypothyroidism Market

Inflammatory Bowel Disease Market

Mayus Kinase Jak Inhibitors Market

Mild Dry Eye Market

Mucopolysaccharidosis Market

Oncolytic Virus Cancer Therapy Market

Pyoderma Gangrenosum Market

Transdermal Drug Delivery Devices Market

Intrathecal Pumps Market

Hedgehog Pathway Inhibitors Market

Yellow Fever Market

Laryngeal Cancer Market

Female Infertility Market

Gender Dysphoria Market

Chronic Brain Damage Market

Spain Healthcare Outlook Market

Malignant Fibrous Histiocytoma Market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services